These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 8331098)

  • 1. Biological approaches to treatment-resistant obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Barr LC; Aronson SC; Price LH
    J Clin Psychiatry; 1993 Jun; 54 Suppl():16-26. PubMed ID: 8331098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of the resistant obsessive-compulsive disorder: an update].
    Crespo Facorro B; Gomez-Hernández R
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(1):61-9. PubMed ID: 9133159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy of obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Price LH
    J Clin Psychiatry; 1992 Apr; 53 Suppl():29-37. PubMed ID: 1532962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies.
    Jenike MA; Rauch SL
    J Clin Psychiatry; 1994 Mar; 55 Suppl():11-7. PubMed ID: 7915709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
    Carpenter LL; McDougle CJ; Epperson CN; Price LH
    Drug Saf; 1996 Aug; 15(2):116-34. PubMed ID: 8884163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on pharmacologic management of OCD: agents and augmentation.
    McDougle CJ
    J Clin Psychiatry; 1997; 58 Suppl 12():11-7. PubMed ID: 9393391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of treatment-refractory obsessive compulsive disorder patients.
    Dominguez RA; Mestre SM
    J Clin Psychiatry; 1994 Oct; 55 Suppl():86-92. PubMed ID: 7961537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Leckman JF; Holzer JC; Barr LC; McCance-Katz E; Heninger GR; Price LH
    Am J Psychiatry; 1993 Apr; 150(4):647-9. PubMed ID: 8465885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy of obsessive-compulsive disorder.
    Ko SM
    Br J Clin Pract; 1995; 49(1):36-9. PubMed ID: 7742183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings.
    Blier P; Bergeron R
    Int Clin Psychopharmacol; 1996 Mar; 11(1):37-44. PubMed ID: 8732312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacotherapy of obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Price LH
    Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of pharmacologic treatments for obsessive-compulsive disorder.
    Kaplan A; Hollander E
    Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system].
    Baving L; Schmidt MH
    Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrated approach to treatment of obsessive compulsive disorder.
    Greist JH
    J Clin Psychiatry; 1992 Apr; 53 Suppl():38-41. PubMed ID: 1532963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.